Two Reasons to Stop By
Our clinical and commercial team will be at booth F4 through all five days of the congress.
Sirolimus for Peripheral Artery Disease
See how our proprietary Nanolute™ drug-delivery technology carries sirolimus into the vessel wall — and what that means for below-the-knee and complex peripheral artery disease (PAD).
The Evidence, First-Hand
Our clinical team will walk you through the MagicTouch sirolimus drug-coated balloon data set — including the SirPAD and SIRONA randomized trials — at the booth, every day.
Evidence at a Glance
Published data from the MagicTouch clinical program — the most clinically studied sirolimus-coated balloon in coronary and peripheral domains.
The world's largest randomized sirolimus drug-coated balloon trial in PAD — an all-comers population with femoropopliteal or below-the-knee disease.
View Clinical Trials →Major adverse limb events vs uncoated balloon — noninferior and superior in the SirPAD primary analysis.
View Clinical Trials →The largest femoropopliteal randomized controlled trial vs paclitaxel drug-coated balloons confirmed non-inferiority of MagicTouch PTA.
View Clinical Trials →What We're Bringing to Copenhagen
Sirolimus drug-coated balloons and drug-delivery technology from a portfolio trusted in 80+ countries. Indications and availability vary by region.
MagicTouch PTA
Sirolimus drug-coated balloon for peripheral artery disease (PTA) — femoropopliteal and below-the-knee interventions.
MagicTouch AVF
Sirolimus drug-coated balloon for arteriovenous fistula (AVF) — maintaining dialysis access patency.
Nanolute™
The proprietary sub-micron sirolimus encapsulation and drug-delivery platform behind the MagicTouch portfolio.
Let's Put Time in the diary.
Tell us what you'd like to discuss and we'll have the right person waiting at booth F4.